Cargando…
Stimulated Reporting of Adverse Events Following Immunization with COVID-19 Vaccines
In India, up until December 2021, Covishield and Covaxin vaccines against COVID-19 were being used for mass vaccination programs. In view of the urgency of fighting the ongoing pandemic, many vaccines have been granted emergency use approval while phase 2/3 clinical trials were still underway. Even...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782407/ https://www.ncbi.nlm.nih.gov/pubmed/36560545 http://dx.doi.org/10.3390/vaccines10122133 |